Member's Email | Search | Sitemap | Contact us
    • Overview
    • Vision & Values
    • Letters from the MD & CEO
    • Businesses
    • Evolution
    • Board of Directors
    • Corporate Citizenship
    • Awards & Recognitions
    • Global Locations
    • Markets
      • Overview
      • India
        • Overview
        • Divisions
        • Strategic Focus
      • Africa & Middle East
      • Asia
      • Russia & CIS
      • Latin America
      • Central Eastern Europe
    • Manufacturing
      Facilities
      • Overview
      • Nasik – India
      • Baddi – India
      • Nalagarh – India
      • Vysoke Myto – Czech
      • Sao Paulo – Brazil
    • Overview
    • New Chemical Entity
      (NCE)
      • Inflammation
      • Metabolic Disorders
      • Pain
      • Gastro Intestinal
    • New Biologics Entity
      (NBE)
      • Inflammation
      • Metabolic Disorder
    • Research Pipeline
    • R&D Centres of
      Excellence
      • Overview
      • Mahape
      • Switzerland
      • Oxford
      • Sinnar
    • Scientific Advisory Board
    • Contacts
    • Financial Results / MD&A
    • Analyst Presentations
    • Annual Report
    • Shareholders Corner
      • Dividend History
      • Shareholder Forms/Queries
    • FAQs
    • Careers Home
      • Overview
      • Awards and Recognitions
      • Values
    • Why Glenmark
      • Reasons to join Glenmark
      • Glenmark Centre of Learning
      • Employee Testimonials
      • Campus Recruitment
    • Apply
      • Current Jobs
      • For Consultants
      • Apply Online
      • FAQs
    • News Releases
    • Media Library
      • Profiles
      • Photo Gallery
      • Fact Sheet

  • Investors

    Financial Result Q1 FY 10-11

    MD & A Q1 FY 10-11

    Investor Presentation - August 2009

    Quick Links

    Global Presence

    NCE Pipeline

    India Formulations

    Careers

    Other Glenmark Websites

  • News

    30 Aug 2010
    Glenmark announces the Discovery of a novel chemical entity 'GRC 17536', a potential first-in-class molecule globally
    16 Aug 2010
    Glenmark Generics receives approval from USFDA for Trospium tablets
    10 Aug 2010
    Glenmark Generics receives approval from USFDA for
  • Glenmark has four R&D Centres of Excellence           

     

     

  • Philosophy Glenmark
    Video

    The New Way in the
    New World

     

    homeflashslug

Home  |  About Glenmark  |  Formulations Business  |  Drugs Discovery |  Investors  |  Careers  |  Newsroom  |  Contact us

Copyright © 2009 Glenmark. All rights reserved